Ulta Beauty: A Strong Contender in the Beauty Retail Market
*Stock prices used were the prices of Jun. 11, 2025. The video was published on Jul. 16, 2025.
Should you invest $1,000 in Ulta Beauty right now?
Before you buy stock in Ulta Beauty, consider this:
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ulta Beauty wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $679,653!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,046,308!*
Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 15, 2025
Nicholas Sciple has no position in any of the stocks mentioned. Tyler Crowe has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Ulta Beauty. The Motley Fool has a disclosure policy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
22 minutes ago
- Globe and Mail
RXST BREAKING NEWS: BFA Law is Investigating RxSight, Inc. for Securities Fraud; Contact the Firm about how to Potentially Recover Investment Losses
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RxSight, Inc. (NASDAQ: RXST) for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: Why is RxSight being Investigated? RxSight is engaged in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses. The Company's main product is its Light Adjustable Lens (LAL) that can be customized after cataract surgery through a series of non-invasive light treatments. These treatments, using a Light Delivery Device (LDD), adjust the lens's shape and power to optimize vision based on the patient's individual needs and preferences. During the relevant period, the Company touted its strong LAL and LDD sales. In reality, RxSight was experiencing a slowdown in LAL utilization that was first noted in 2024. The Stock Declines as the Truth is Revealed On April 3, 2025, before the market opened, RxSight cut its 2025 full-year revenue forecast citing a 'softening' of the market that purportedly occurred 'in the second half of 2024.' On this news, the price of RxSight stock declined roughly 38%, from $26.12 per share on April 2, 2025, to $16.21 per share on April 3, 2025. Then on July 8, 2025, the Company further cut its 2025 full-year revenue forecast. RxSight attributed the adjustment to 'the slower ramp in LAL utilization that was first noted in 2024.' On this news, the price of RxSight stock declined roughly 38%, from $12.79 per share on July 8, 2025, to $7.95 per share on July 9, 2025. Click here for more information: What Can You Do? If you invested in RxSight you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz ross@ 212-789-3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit
CTV News
22 minutes ago
- CTV News
Foreign investors continue to reduce exposure to Canadian equities: StatCan
Statistics Canada building and signs are pictured in Ottawa on July 3, 2019. THE CANADIAN PRESS/Sean Kilpatrick New data suggests that Canadian securities are falling out of favour with foreign investors, while Canadians are investing more of their money abroad. On Thursday, Statistics Canada released tracking data on Canada's international securities transactions in May, which found there was 'strong foreign divestment in Canadian shares' during the month. 'Foreign investors reduced their holdings of Canadian securities by $2.8 billion in May, a fourth consecutive monthly divestment,' the agency said in a release. 'In May, non-resident investors reduced their exposure to Canadian shares by $11.4 billion. On a sector basis, the divestment in May was widespread, led by shares from the energy and mining, management of companies and enterprises, as well as manufacturing sectors.' Foreign investors did, however, increase their holdings of Canadian government bonds, acquiring $13.1 billion compared to a $25.1 billion divestment in April. 'The activity in May reflected foreign acquisitions of provincial (+$8.0 billion) and federal (+$6.9 billion) government bonds, which were moderated by a divestment of $4.2 billion in private corporate bonds,' said StatCan. Despite the overall divestment in Canadian shares, Canada's benchmark stock index, the S&P/TSX composite, increased by 5.4 per cent in May compared to April after three consecutive monthly declines. Canadians move money out Canadian investors, meanwhile, increased their exposure to foreign securities by $13.4 billion in May, up significantly from $4.1 billion the month before, according to StatCan. 'In May, investors targeted U.S. shares, while reducing their exposure to U.S. government debt instruments,' the agency said. 'Canadian investors bought $11.5 billion of foreign shares in May, the largest investment since February. Sizable acquisitions of U.S. shares (+$14.2 billion) in May were moderated by sales of non-U.S. shares (-$2.8 billion).' The benchmark American stock index, the S&P 500, increased by more than six per cent in May compared to April after it, like the TSX, had declined for three straight months prior. StatCan said that when it came to Canadian purchases of foreign debt securities in May, investors mainly purchased U.S. corporate bonds and non-U.S. bonds, while reducing their holdings of U.S. government bonds and Treasury bills. As a result of increased investment abroad and the foreign divestment of Canadian securities, Canada saw a net outflow of $16.2 billion from its economy in May, marking 'a fourth consecutive month of net outflows, bringing the total to $83.9 billion,' said StatCan.
Globe and Mail
22 minutes ago
- Globe and Mail
PNC Financial Reports Strong Q2 2025 Results
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. PNC Financial ( (PNC)) has issued an announcement. On July 16, 2025, PNC Financial Services Group reported strong financial results for the second quarter of 2025, with a net income of $1.6 billion and a 4% revenue growth. The company experienced its strongest loan growth since the fourth quarter of 2022, maintained stable noninterest expenses, and announced a dividend increase, reflecting its continued financial strength. PNC's strategic priorities include expanding its client base and leveraging technology for superior client service, which contributed to record treasury management revenue and increased brokerage assets. The company also reported improved credit quality and maintained its stress capital buffer at the regulatory minimum. The most recent analyst rating on (PNC) stock is a Buy with a $212.00 price target. To see the full list of analyst forecasts on PNC Financial stock, see the PNC Stock Forecast page. Spark's Take on PNC Stock According to Spark, TipRanks' AI Analyst, PNC is a Outperform. PNC Financial's strong financial performance and strategic focus on capital return are the most significant factors driving the score. The technical analysis suggests caution due to overbought signals, while the valuation remains fair with an attractive dividend yield. The earnings call reinforces confidence in PNC's resilience despite potential market challenges. To see Spark's full report on PNC stock, click here. More about PNC Financial PNC Financial Services Group, Inc. operates in the financial services industry, offering a wide range of financial products and services on a national basis. The company focuses on corporate banking, business credit, treasury management, retail banking, and asset management, leveraging technology to enhance client service and ensure safety and soundness. Average Trading Volume: 2,267,611 Technical Sentiment Signal: Strong Buy Current Market Cap: $78.08B For detailed information about PNC stock, go to TipRanks' Stock Analysis page.
